Determining the Effect of Abacavir on Platelet Activation in HIV positive men

Determining the Effect in HIV positive men of Abacavir administration on markers of Platelet Activation

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613000570785

Enrollment

Registered

2013-05-20

Start date

2013-08-01

Completion date

2014-03-14

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

open label single arm self-controlled trial of the affect of 15 days of abacavir on platelet function in healthy HIV positive volounteers

Interventions

Abacavir 600mg (2x 300mg oral tablets) daily for 15 days. Adherence assessed by compliance questionaire and tablet return at day 15 visit

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

HIV positive men with well controlled HIV (undetectable viral load for > six months) on a non-abacavir containing antiretroviral regimen

Exclusion criteria

Previous allergy to abacavir or HLA*B*57*01 positivity High Cardiovascular risk Platelet disorder Current or recent use of antiplatelets

Outcome results